Kahl Anna L, Kirchhof Julia, Füting Anna, Hütter Bernd-Otto, Wilde Benjamin, Witzke Oliver, Benson Sven, Hadamitzky Martin, Schedlowski Manfred
aInstitute of Medical Psychology and Behavioral Immunobiology Departments of bNeurosurgery cNephrology dInfectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Behav Pharmacol. 2017 Jun;28(4):255-261. doi: 10.1097/FBP.0000000000000281.
There is clinical and experimental evidence that treatment with immunosuppressive and antiproliferative drugs such as the calcineurin inhibitor cyclosporine A (CsA) is associated with mental health problems and neuropsychological disturbances in patients. However, it remains unclear whether and to what extent cognitive functions such as memory and attention processes are affected by the pharmacological treatment. This is partly because of the fact that it is difficult to refer the observed neuropsychological disturbances in patients to the drug itself, to drug-induced immune suppression, or to interaction with other medication or comorbidities. Thus, in a double-blind study with healthy male participants (n=30), we investigated whether short-term intake of therapeutic doses of CsA (4×2.5 mg/kg) affects attention, working memory performance, and anxiety levels, measured with the Tests of Attentional Performance and the State-Trait Anxiety Inventory. The data indicate that short-term CsA-administration and subsequent suppression in interleukin-2 production are accompanied neither by a decrease in attention or memory performance nor by increased anxiety levels in healthy male volunteers, suggesting that the short-term intake of CsA does not impair cognitive functioning. Further studies in healthy humans are needed to determine neurocognitive functions and mood states after short-term or subchronic treatment with different immunosuppressive and antiproliferative drugs.
有临床和实验证据表明，使用免疫抑制和抗增殖药物（如钙调神经磷酸酶抑制剂环孢素A（CsA））进行治疗与患者的心理健康问题和神经心理障碍有关。然而，药物治疗是否以及在何种程度上影响记忆和注意力等认知功能仍不清楚。部分原因在于，很难将患者中观察到的神经心理障碍归因于药物本身、药物诱导的免疫抑制，或与其他药物或合并症的相互作用。因此，在一项针对健康男性参与者（n = 30）的双盲研究中，我们使用注意力表现测试和状态-特质焦虑量表，调查了短期摄入治疗剂量的CsA（4×2.5mg/kg）是否会影响注意力、工作记忆表现和焦虑水平。数据表明，在健康男性志愿者中，短期给予CsA及随后白细胞介素-2生成受到抑制，既不会导致注意力或记忆表现下降，也不会使焦虑水平升高，这表明短期摄入CsA不会损害认知功能。需要对健康人群进行进一步研究，以确定不同免疫抑制和抗增殖药物短期或亚慢性治疗后的神经认知功能和情绪状态。
